Physician profile
Nancy Hill
NPI 1770161978
$5,860.59
in general payments reported to CMS, 2019-2025
12 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $524 · 2022: $1,763 · 2023: $2,068 · 2024: $1,271 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,493 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,492.80 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,148.81 | 2021-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $981.85 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $827.99 | 2021-2025 | Caplyta |
| Abbvie INC. | $787.97 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $695.37 | 2021-2024 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $414.91 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Indivior INC. | $351.12 | 2022-2024 | Perseris |
| Neurocrine Biosciences, INC. | $335.37 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $115.40 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $77.21 | 2024 | Auvelity |
| Lundbeck LLC | $66.53 | 2021-2024 | Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $58.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.